Many people experiencing apparent medication tolerance are actually experiencing absorption inconsistency from overused injection sites
Thus, potentially effective drugs may act on common links between different pathologies, as well as specific pathological mechanisms
First cardiovascular safety trial of a DPP-4 inhibitor in patients with T2DM and high cardiovascular risk, showing that saxagliptin does not augment MACE but increases hospitalization for heart failure
Protective effect of sitagliptin against renal ischemia reperfusion injury in rats
We'll schedule your follow-up to monitor progress
Remarkably, the survival benefits of GLP-1RAs, as observed in CVOTs, typically manifest over a more extended period than what our Kaplan Meier curves suggest 15,33